Mazdutide Reference

Plain English

What it is

Mazdutide is an experimental weight medicine that works on two natural gut-hormone pathways at the same time (called GLP-1 and glucagon), which help curb appetite and how the body uses energy. It is given as a shot under the skin. China approved it for weight management in 2025, but in the United States it is still being tested and is not approved by the FDA.

What people use it for

It is used to help adults who carry extra weight lose weight and keep it off over the long term. It is also being studied for blood sugar control in type 2 diabetes and for other conditions.

What the science shows

In a large, carefully run trial in China (called GLORY-1), adults with obesity lost a meaningful amount of weight over about a year compared with people given a dummy injection. The most common side effects were stomach and gut problems like nausea, diarrhea, and vomiting, and most were mild to moderate. Because the main human studies were done in Chinese adults, how well it works and how safe it is for other groups is still less certain.

The catch

Mazdutide is not approved by the FDA in the United States, so outside of a clinical trial it is not legally available there, and any version sold online in the US is not the approved or trial medicine and could be unsafe or fake. The strongest evidence so far comes from one population, so longer-term and broader-group results are still being learned.

Reference summary

GLORY-1 (Ji 2025 NEJM, Phase 3, Chinese adults with obesity or overweight, 48 weeks) reported clinically meaningful placebo-subtracted weight reductions at both the 4 mg and 6 mg once-weekly doses, in the range typically reported for GLP-1 / glucagon dual agonists in similar populations. Adverse events were predominantly gastrointestinal (nausea, diarrhea, vomiting), dose-dependent, with most events graded mild to moderate. The trial was conducted in a Chinese population and the Phase 3 program outside of China is at earlier stages.

Regulatory and posture

Categories

GLP-1, Fat Loss

Aliases

IBI362, LY3305677, GLP-1 / glucagon dual receptor agonist

Evidence posture

human - Phase 3 data exist in a Chinese population. Approved in China 2025; investigational outside China.

Regulatory status

Investigational in the United States. Mazdutide is Innovent Biologics' GLP-1 / glucagon dual receptor agonist (originally licensed from Eli Lilly). China's NMPA approved mazdutide in 2025 for adults with obesity or overweight (the first dual-agonist approval in China for this indication). There is no FDA-approved drug label in the US or EU, and mazdutide is not on FDA's approved bulk-substances list for compounding.

Content review status

investigational verified

Related tools

• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• GLP-1 taper planner overview - Public overview of the Pro GLP-1 taper planner.
• Plateau analyzer overview - Public overview of the Pro plateau-pattern analyzer.